Amyloid β-protein affects cholesterol metabolism in cultured neurons: Implications for pivotal role of cholesterol in the amyloid cascade

Journal of Neuroscience Research

Volumn 70, Issue 3, 2002, Pages 438-446

  Gong, Jian Sheng ^a   Sawamura, Naoya ^a   Zou, Kun ^a   Sakai, Juro ^b   Yanagisawa, Katsuhiko ^a   Michikawa, Makoto ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; Amyloid protein; Cholesterol; Cholesterol release; Cholesterol synthesis; Tau phosphorylation

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; CHOLESTEROL; LACTATE DEHYDROGENASE; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL DEATH; CELL VIABILITY; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME RELEASE; LIPID METABOLISM; MOLECULAR MECHANICS; NERVE CELL CULTURE; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CCAAT-ENHANCER-BINDING PROTEINS; CELL DEATH; CELL MEMBRANE; CELL SURVIVAL; CELLS, CULTURED; CHOLESTEROL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HYDRO-LYASES; NEURONS; PEPTIDE FRAGMENTS; RATS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TAU PROTEINS; TRANSCRIPTION FACTORS;

EID: 0037010287     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10347     Document Type: Article

References (49)

1. Andrews NC, Faller DV. 1991. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499.
2. Avdulov NA, Chochina SV, Igbavboa U, Warden CS, Vassiliev AV, Wood WG. 1997. Lipid binding to amyloid β-peptide aggregates: Preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J Neurochem 69:1746-1752.
3. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. 1996. Amyloid β-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271:32916-32922.
4. Brown MS, Goldstein JL. 1997. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331-340.
5. Busciglio J, Lorenzo A, Yeh J, Yankner BA. 1995. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14:879-888.
6. Chochina SV, Avdulov NA, Igbavboa U, Cleary JP, O'Hare EO, Wood WG. 2001. Amyloid β-peptide1-40 inreases neuronal membrane fluidity: Role of cholesterol and brain region. J Lipid Res 42:1292-1297.
7. Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK. 1997. Acceleration of amyloid fibril formation by specific binding of Aβ(1-40) peptide to ganglioside-containing membrane vesicles. J Biol Chem 272:22987-22990.
8. El-Agnaf OM, Nagala S, Patel BP, Austen BM. 2001. Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J Mol Biol 310:157-168.
9. Esiri M, Hyman B, Beyreuther K, Masters C. 1997. Aging and dementia. In: Graham D, Lantos P, editors. Greenfield's Neuropathology. London: Arnold. p 153-233.
10. Fagan AM, Younkin LH, Morris JC, Fryer JD, Cole TG, Younkin SG, Holtzman DM. 2000. Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol 48:201-210.
11. Fan QW, Wei Y, Senda T, Yanagisawa K, Michikawa M. 2001. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem 76:391-400.
12. Fan QW, Yu W, Gong JS, Zou K, Sawamura N, Senda T, Yanagisawa K, Michikawa M. 2002. Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons. J Neurochem 80:178-190.
13. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz HR, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. 2001. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856-5861.
14. Hardy JA, Higgins GA. 1992. Alzheimer's disease: The amyloid cascade hypothesis. Science 256:184-185.
15. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ. 1999. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19:8876-8884.
16. Hartmann T. 2001. Cholesterol, Aβ and Alzheimer's disease. Trends Neuorsci 24:S45-48.
17. Jick HR, Zomberg GL, Jick SS, Seshadri S, Drachman DA. 2000. Statins and the risk of dementia. Lancet 356:1627-1631.
18. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. 2001. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci USA 98:5815-5820.
19. Koudinov A, Matsubara E, Frangione B, Ghiso J. 1994. The soluble form of Alzheimer's amyloid β-protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 205:1164-1171.
20. Koudinov AR, Koudinova NV. 2001. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 15:1858-1860.
21. Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J. 1996. Biochemical characterization of Alzheimer's soluble amyloid β-protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem Biophys Res Commun 223:592-597.
22. Koudinova NV, Berezov TT, Koudinov AR. 1996. Multiple inhibitory effects of Alzheimer's peptide Aβ1-40 on lipid biosynthesis in cultured human HepG2 cells. FEBS Lett 395:204-206.
23. Koudinova NV, Koudinov AR, Yavin E. 2000. Alzheimer's Aβ1-40 peptide modulates lipid synthesis in neuronal cultures and intact rat fetal brain under normoxic and oxidative stress conditions. Neurochem Res 25:653-660.
24. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. 1998. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Nad Acad Sci USA 95:6448-6453.
25. Launer LJ, White LR, Petrovitch HR, Ross GW, Curb JD. 2001. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 57:1447-1452.
26. Lorenzo A, Yankner BA. 1994. β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 91:12243-12247.
27. Mason RP, Estermyer JD, Kelly JF, Mason PE. 1996. Alzheimer's disease amyloid β-peptide 25-35 is localized in the membrane hydrocarbon core: x-ray diffraction analysis. Biochem Biophys Res Commun 222:78-82.
28. Mason RP, Jacob RF, Walter MF, Mason PE, Avdulov NA, Chochina SV, Igbavboa U, Wood WG. 1999. Distribution and fluidizing action of soluble and aggregated amyloid β-peptide in rat synaptic plasma membranes. J Biol Chem 274:18801-18807.
29. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M. 1999. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45:537-541.
30. Mattson MP, Tomaselli KJ, Rydel RE. 1993. Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res 621:35-49.
31. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW. 2001. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294:1354-1357.
32. McLaurin J, Chakrabartty A. 1996. Membrane disruption by Alzheimer β-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J Biol Chem 271:26482-26489.
33. Michikawa M, Yanagisawa K. 1998. Apolipoprotein E4 induces neuronal cell death under conditions of suppressed de novo cholesterol synthesis. J Neurosci Res 54:58-67.
34. Michikawa M, Yanagisawa K. 1999. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J Neurochem 72:2278-2285.
35. Michikawa M, Fan QW, Isobe I, Yanagisawa K. 2000. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 74:1008-1016.
36. Michikawa M, Gong JS, Fan QW, Sawamura N, Yanagisawa K. 2001. A novel action of amyloid β-protein (Aβ): Oligomeric Aβ promotes lipid efflux. J Neurosci 21:7226-7235.
37. Muller WE, Koch S, Eckert A, Hartmann HR, Scheuer K. 1995. β-Amyloid peptide decreases membrane fluidity. Brain Res 674:133-136.
38. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A. 1998. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17:14-20.
39. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. 1993. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J Neurosci 13:1676-1687.
40. Sawamura N, Gong JS, Garver WS, Heidenreich RA, Ninomiya HR, Ohno K, Yanagisawa K, Michikawa M. 2001. Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem 276:10314-10319.
41. Selkoe DJ. 1994. Alzheimer's disease: A central role for amyloid. J Neuropathol Exp Neurol 53:438-447.
42. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. 1998. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Nad Acad Sci USA 95:6460-6464.
43. Simons M, Keller P, Dichgans J, Schulz JB. 2001. Cholesterol and Alzheimer's disease: Is there a link? Neurology 57:1089-1093.
44. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. 1993. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci USA 90:7789-7793.
45. Terzi E, Holzemann G, Seelig J. 1995. Self-association of β-amyloid peptide (1-40) in solution and binding to lipid membranes. J Mol Biol 252:633-642.
46. Wolozin B, Kellman W, Kuosseau P, Celesia GG, Siegel G. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443.
47. Yanagisawa K, Odaka A, Suzuki N, Ihara Y. 1995. GM1 gangliosidebound amyloid β-protein (Aβ): A possible form of preamyloid in Alzheimer's disease. Nat Med 1:1062-1066.
48. Yang J, Brown MS, Ho YK, Goldstein JL. 1995. Three different rearrangements in a single intron truncate sterol regulatory element binding protein-2 and produce sterol-resistant phenotype in three cell lines. Role of introns in protein evolution. J Biol Chem 270:12152-12161.
49. Yip CM, Elton EA, Darabie AA, Morrison MR, McLaurin J. 2001. Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis and neurotoxicity. J Mol Biol 311:723-734.